KRAS and cancer: Evidence supporting dose escalation in the setting of K-RAS mutant colorectal [26,27,28,29,30] cancer suggests intrinsic biology matters; however, neither molecular subtype or BED >100 Gy3 impacted primary or secondary outcomes in this retrospective review.